• Alexandre Yazigi, Viviane Chalhoub, Samia Madi-Jebara, Fadia Haddad, and Gemma Hayek.
• Department of Anesthesia and Intensive Care, Hotel-Dieu de France Hospital, Saint-Joseph University, Beirut, Lebanon.
• J Clin Anesth. 2002 May 1;14(3):183-6.

Study ObjectivesTo assess the safety and efficacy of ondansetron for prevention of pruritus, nausea and vomiting after cesarean delivery with intrathecal sufentanil-morphine.DesignRandomized, double-blind, placebo-controlled study.SettingReferral center, institutional practice.Patients100 nonbreastfeeding women undergoing elective cesarean delivery with sufentanil-morphine-bupivacaine anesthesia.InterventionsAfter the umbilical cord was clamped, patients in Group 1 received ondansetron 8 mg intravenously (IV) and patients in Group 2 received placebo.MeasurementsFrequency and severity of postoperative (24-hour) pruritus, nausea and vomiting, surgical pain, and side effects related to ondansetron were recorded.Main ResultsIn the ondansetron group, 38 patients had pruritus (16 mild and 22 severe) and 9 patients had nausea and vomiting (5 mild and 4 severe). In the placebo group, 41 patients had pruritus (21 mild and 20 severe) and 29 patients had nausea and vomiting (9 mild and 15 severe). The frequency and severity of the nausea and vomiting episodes were significantly reduced in the ondansetron group. Pain scores were comparable between groups. No side effects related to ondansetron were reported.ConclusionsProphylactic IV ondansetron 8 mg is safe and effective in reducing the frequency and the severity of nausea and vomiting, but not pruritus, following cesarean delivery with intrathecal sufentanil-morphine.

24 keywords...

hide…